

25th October, 2024

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Sub: Update on acquisition of additional equity interest in Cipla (Jiangsu) Pharmaceuticals Co., Ltd.

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 25th September, 2024, we hereby notify that Cipla (EU) Limited, wholly owned subsidiary of the Company in UK has completed all the conditions with respect to acquisition of 6.9124% equity interest in Cipla (Jiangsu) Pharmaceuticals Co. Ltd., China (“Cipla Jiangsu”) on 25th October, 2024. Cipla Jiangsu is now a wholly owned step-down subsidiary of the Company.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode